Licensing status

Publication and contact information

Infectious disease

Infectious disease

Transforming growth factor-b (TGFB; TGF-b); integrin aVb8

Mouse studies suggest inhibiting TGF-b or integrin aVb8 could help prevent chronic helminth infection. In Trichuris muris egg-infected mouse models of helminth infection, Tgf-b signaling on Cd4+ T cells was higher than that in uninfected controls. In these models, an anti-TGF-b antibody decreased worm burden-a marker of chronic infection-compared with an inactive control antibody. Also in these models, an integrin aVb8 deficiency on dendritic cells decreased Tgf-b signaling in Cd4+ T cells compared with normal expression of integrin aVb8 and led to a consequent reduction in worm burden. Ongoing work includes investigating whether the integrin aVb8-TGF-b pathway is involved in other infectious diseases.
Acceleron Pharma Inc. and Celgene Corp. have ACE-536, a modified activin receptor type 2B (ACVR2B) fusion protein that inhibits several ligands in the TGF-b superfamily, in Phase II testing to treat anemia and thalassemia.
BTG plc has Pleneva (BGC20-0134), an oral TGFB1 immunomodulator, in Phase II testing to treat multiple sclerosis (MS).
Eli Lilly and Co.'s LY2382770, a neutralizing mAb against TGFB1, is in Phase II testing to treat diabetic nephropathy and renal disease.

SciBX 6(43); doi:10.1038/scibx.2013.1226
Published online Nov. 7, 2013

Unpatented; unlicensed

Worthington, J.J. et al. PLoS Pathog.; published online Oct. 3, 2013;
Contact: Mark A. Travis,
The University of Manchester,
Manchester, U.K.